Skip to main content
Vaishali Pharma Limited logo

Vaishali Pharma Limited — Investor Relations & Filings

Ticker · VAISHALI ISIN · INE972X01022 LEI · 335800LHHVE3JLLKP681 National Stock Exchange of India Wholesale and retail trade
Filings indexed 428 across all filing types
Latest filing 2023-09-05 Board/Management Inform…
Country IN India
Listing National Stock Exchange of India VAISHALI

About Vaishali Pharma Limited

https://www.vaishalipharma.com/

Vaishali Pharma Limited specializes in the sourcing, marketing, and distribution of a comprehensive range of healthcare products. The company’s portfolio encompasses Active Pharmaceutical Ingredients (APIs), finished formulations in various dosage forms such as tablets and injectables, and surgical supplies. It also provides veterinary products, herbal supplements, and nutraceuticals. The business model focuses on integrated supply chain management, facilitating the movement of medical products from manufacturing units to global markets. By adhering to international quality standards and leveraging an extensive distribution network, the company serves diverse therapeutic requirements. Its operations emphasize reliability in procurement and the delivery of cost-effective healthcare solutions to a global clientele across multiple regions, including Africa, Asia, and Latin America.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to the National Stock Exchange of India Limited, reporting the outcome of a Board Meeting held on September 5, 2023. It details approvals made by the Board, including the Board's Report for the year ended March 31, 2023, approval of the AGM notice, closure of register of members for the AGM, re-appointment of a director, and approval of remuneration. The document is an announcement of the decisions taken at the Board Meeting rather than the full Board Report or Annual Report itself. It is not a full financial report but a regulatory announcement about board decisions and meeting outcomes. Therefore, it fits best under Board/Management Information (MANG). The document length is short (2423 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2023-09-05 English
Financial Result Updates
Regulatory Filings
2023-08-07 English
Outcome of Board Meeting
Regulatory Filings
2023-08-07 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice from Vaishali Pharma Limited to the National Stock Exchange of India about an upcoming Board Meeting scheduled for August 7, 2023. The purpose of the meeting is to consider and approve the Standalone Un-Audited Financial Results for the quarter ended June 30, 2023. The document also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (1854 characters) and serves as an intimation or announcement of a board meeting rather than containing any financial results or detailed reports itself. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER), but rather a Regulatory Filing (RNS) as it is a general regulatory announcement related to compliance and meeting scheduling.
2023-07-31 English
Board Meeting — VAISHALI PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 07-Aug-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2023-07-31 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate addressed to the National Stock Exchange of India Limited regarding Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2023. It is a letter confirming that the regulation is not applicable as all shares are in demat form and no rematerialisation requests were received. The document is short (2337 characters) and primarily serves as a certification or attestation rather than containing substantive financial data or a full report. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a compliance certificate and not a full interim or quarterly report.
2023-07-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.